Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $51.08, but opened at $49.20. Tarsus Pharmaceuticals shares last traded at $51.00, with a volume of 44,744 shares trading hands.
Wall Street Analysts Forecast Growth
TARS has been the subject of a number of research reports. The Goldman Sachs Group increased their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a research note on Friday, November 15th. William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, August 30th. Finally, Oppenheimer raised their target price on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $54.20.
Read Our Latest Research Report on TARS
Tarsus Pharmaceuticals Price Performance
The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a market cap of $2.01 billion, a PE ratio of -13.78 and a beta of 1.04. The firm has a 50 day moving average of $44.72 and a two-hundred day moving average of $34.38.
Hedge Funds Weigh In On Tarsus Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC raised its holdings in Tarsus Pharmaceuticals by 16.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company's stock worth $6,924,000 after acquiring an additional 29,465 shares during the last quarter. Creative Planning bought a new stake in shares of Tarsus Pharmaceuticals in the 3rd quarter worth $362,000. Essex Investment Management Co. LLC purchased a new position in shares of Tarsus Pharmaceuticals in the third quarter worth $3,590,000. Vestal Point Capital LP bought a new position in shares of Tarsus Pharmaceuticals during the third quarter valued at $7,565,000. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Tarsus Pharmaceuticals by 7.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company's stock valued at $37,536,000 after purchasing an additional 77,825 shares in the last quarter. 90.01% of the stock is currently owned by institutional investors.
Tarsus Pharmaceuticals Company Profile
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Further Reading
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
